Shaping the repertoire of tumor-infiltrating effector and regulatory T cells

Immunological Reviews

Volumn 259, Issue 1, 2014, Pages 245-258

  Savage, Peter A ^a   Leventhal, Daniel S ^a   Malchow, Sven ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Aire; Antigen; Foxp3; Regulatory T cells; Tolerance; Tumor

Indexed keywords

AUTOIMMUNE REGULATOR PROTEIN; DIFFERENTIATION ANTIGEN; MELAN A; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; EFFECTOR CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

AIRE; ANTIGEN; FOXP3; REGULATORY T CELLS; TOLERANCE; TUMOR;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; AUTOIMMUNITY; CLONAL SELECTION, ANTIGEN-MEDIATED; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; NEOPLASMS; PROSTATE; T-LYMPHOCYTES, REGULATORY; THYMUS GLAND; TRANSCRIPTION FACTORS; TUMOR MICROENVIRONMENT;

EID: 84897953576     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12166     Document Type: Article

References (102)

1. Foley EJ. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res 1953;13:835-837.
2. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957;18:769-778.
3. Klein G, Sjogren HO, Klein E, Hellstrom KE. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 1960;20:1561-1572.
4. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012;12:269-281.
5. Dudley ME, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-854.
6. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
7. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011;11:805-812.
8. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med 2014;65:185-202.
9. Davis MM, et al. T cells as a self-referential, sensory organ. Annu Rev Immunol 2007;25:681-695.
10. Wang RF. Identification of MHC class II-restricted tumor antigens recognized by CD4+ T cells. Methods 2003;29:227-235.
11. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012;30:531-564.
12. Deleeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 2012;18:3022-3029.
13. Savage PA, Malchow S, Leventhal DS. Basic principles of tumor-associated regulatory T cell biology. Trends Immunol 2013;34:33-40.
14. Gajewski TF, Chesney J, Curriel TJ. Emerging strategies in regulatory T-cell immunotherapies. Clin Adv Hematol Oncol 2009;7:1-10.
15. Menetrier-Caux C, et al. Targeting regulatory T cells. Target Oncol 2012;7:15-28.
16. Hewitt HB, Blake ER, Walder AS. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer 1976;33:241-259.
17. Gillis S, Smith KA. Long term culture of tumour-specific cytotoxic T cells. Nature 1977;268:154-156.
18. Gillis S, Baker PE, Ruscetti FW, Smith KA. Long-term culture of human antigen-specific cytotoxic T-cell lines. J Exp Med 1978;148:1093-1098.
19. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-365.
20. van der Bruggen P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-1647.
21. Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P. Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun 2013;13:15.
22. Schietinger A, Philip M, Schreiber H. Specificity in cancer immunotherapy. Semin Immunol 2008;20:276-285.
23. Skipper JC, et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996;183:527-534.
24. Altman JD, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-96.
25. Lee PP, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677-685.
26. Romero P, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998;188:1641-1650.
27. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 1999;162:2227-2234.
28. Kvistborg P, et al. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 2012;1:409-418.
29. Andersen RS, et al. Dissection of T-cell antigen specificity in human melanoma. Cancer Res 2012;72:1642-1650.
30. Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann NY Acad Sci 2013;1284:1-5.
31. Vogelstein B, et al. Cancer genome landscapes. Science 2013;339:1546-1558.
32. Segal NH, et al. Epitope landscape in breast and colorectal cancer. Cancer Res 2008;68:889-892.
33. Robbins PF, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013;19:747-752.
34. van Rooij N, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013;31:e439-e442.
35. Savage PA, et al. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science 2008;319:215-220.
36. Drake CG, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005;7:239-249.
37. Anderson MJ, Shafer-Weaver K, Greenberg NM. HurwitzAA. Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J Immunol 2007;178:1268-1276.
38. Shafer-Weaver KA, et al. Cutting edge: tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells. J Immunol 2009;183:4848-4852.
39. Vlad G, Cortesini R, Suciu-Foca N. CD8+ T suppressor cells and the ILT3 master switch. Hum Immunol 2008;69:681-686.
40. Shi Z, et al. Human CD8+CXCR3+ T cells have the same function as murine CD8+CD122+ Treg. Eur J Immunol 2009;39:2106-2119.
41. Kim HJ, Cantor H. Regulation of self-tolerance by Qa-1-restricted CD8(+) regulatory T cells. Semin Immunol 2011;23:446-452.
42. Surh CD, Sprent J. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 1994;372:100-103.
43. Laufer TM, DeKoning J, Markowitz JS, Lo D, Glimcher LH. Unopposed positive selection and autoreactivity in mice expressing class II MHC only on thymic cortex. Nature 1996;383:81-85.
44. van Meerwijk JP, et al. Quantitative impact of thymic clonal deletion on the T cell repertoire. J Exp Med 1997;185:377-383.
45. Merkenschlager M, et al. How many thymocytes audition for selection? J Exp Med 1997;186:1149-1158.
46. Zerrahn J, Held W, Raulet DH. The MHC reactivity of the T cell repertoire prior to positive and negative selection. Cell 1997;88:627-636.
47. Stritesky GL, et al. Murine thymic selection quantified using a unique method to capture deleted T cells. Proc Natl Acad Sci USA 2013;110:4679-4684.
48. Moran AE, et al. T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. J Exp Med 2011;208:1279-1289.
49. Gardner JM, et al. Deletional tolerance mediated by extrathymic Aire-expressing cells. Science 2008;321:843-847.
50. Lee JW, et al. Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self. Nat Immunol 2007;8:181-190.
51. Rizzuto GA, et al. Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 2009;206:849-866.
52. Blattman JN, et al. Estimating the precursor frequency of naive antigen-specific CD8 T cells. J Exp Med 2002;195:657-664.
53. Obar JJ, Khanna KM, Lefrancois L. Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. Immunity 2008;28:859-869.
54. Hsieh CS, Lee HM, Lio CW. Selection of regulatory T cells in the thymus. Nat Rev Immunol 2012;12:157-167.
55. Jordan MS, et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol 2011;2:301-306.
56. Apostolou I, Sarukhan A, Klein L, von Boehmer H. Origin of regulatory T cells with known specificity for antigen. Nat Immunol 2002;3:756-763.
57. Lee HM, Bautista JL, Scott-Browne J, Mohan JF, Hsieh CS. A broad range of self-reactivity drives thymic regulatory T cell selection to limit responses to self. Immunity 2012;37:475-486.
58. Bilate AM, Lafaille JJ. Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annu Rev Immunol 2012;30:733-758.
59. Lathrop SK, et al. Peripheral education of the immune system by colonic commensal microbiota. Nature 2011;478:250-254.
60. Belkaid Y, Tarbell K. Regulatory T cells in the control of host-microorganism interactions. Annu Rev Immunol 2009;27:551-589.
61. Josefowicz SZ, et al. Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature 2012;482:395-399.
62. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010;31:220-227.
63. Getnet D, et al. Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells. J Immunol 2009;182:4675-4685.
64. Zhou G, Levitsky HI. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol 2007;178:2155-2162.
65. Malchow S, et al. Aire-dependent thymic development of tumor-associated regulatory T cells. Science 2013;339:1219-1224.
66. Hindley JP, et al. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Res 2011;71:736-746.
67. Sainz-Perez A, Lim A, Lemercier B, Leclerc C. The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed towards public sequences. Cancer Res 2012;72:3557-3569.
68. Hsieh CS, et al. Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. Immunity 2004;21:267-277.
69. Wong J, et al. Adaptation of TCR repertoires to self-peptides in regulatory and nonregulatory CD4+ T cells. J Immunol 2007;178:7032-7041.
70. Garcia KC, Teyton L, Wilson IA. Structural basis of T cell recognition. Annu Rev Immunol 1999;17:369-397.
71. Bautista JL, et al. Intraclonal competition limits the fate determination of regulatory T cells in the thymus. Nat Immunol 2009;10:610-617.
72. Li J, Park J, Foss D, Goldschneider I. Thymus-homing peripheral dendritic cells constitute two of the three major subsets of dendritic cells in the steady-state thymus. J Exp Med 2009;206:607-622.
73. Bonasio R, et al. Clonal deletion of thymocytes by circulating dendritic cells homing to the thymus. Nat Immunol 2006;7:1092-1100.
74. Kyewski B, Klein L. A central role for central tolerance. Annu Rev Immunol 2006;4:571-606.
75. Anderson MS, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 2002;298:1395-1401.
76. Derbinski J, et al. Promiscuous gene expression in thymic epithelial cells is regulated at multiple levels. J Exp Med 2005;202:33-45.
77. Aaltonen J. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 1997;17:399-403.
78. Nagamine K, et al. Positional cloning of the APECED gene. Nat Genet 1997;17:393-398.
79. Ramsey C, et al. Aire deficient mice develop multiple features of APECED phenotype and show altered immune response. Hum Mol Genet 2002;11:397-409.
80. Hubert FX, et al. Aire-deficient C57BL/6 mice mimicking the common human 13-base pair deletion mutation present with only a mild autoimmune phenotype. J Immunol 2009;182:3902-3918.
81. Kuroda N, et al. Development of autoimmunity against transcriptionally unrepressed target antigen in the thymus of Aire-deficient mice. J Immunol 2005;174:1862-1870.
82. Jiang W, Anderson MS, Bronson R, Mathis D, Benoist C. Modifier loci condition autoimmunity provoked by Aire deficiency. J Exp Med 2005;202:805-815.
83. Anderson MS, et al. The cellular mechanism of Aire control of T cell tolerance. Immunity 2005;23:227-239.
84. Liston A, Lesage S, Wilson J, Peltonen L, Goodnow CC. Aire regulates negative selection of organ-specific T cells. Nat Immunol 2003;4:350-354.
85. Su MA, et al. Mechanisms of an autoimmunity syndrome in mice caused by a dominant mutation in Aire. J Clin Invest 2008;118:1712-1726.
86. Taniguchi RT, et al. Detection of an autoreactive T-cell population within the polyclonal repertoire that undergoes distinct autoimmune regulator (Aire)-mediated selection. Proc Natl Acad Sci USA 2012;109:7847-7852.
87. Zhu ML, Nagavalli A, Su MA. Aire deficiency promotes TRP-1-specific immune rejection of melanoma. Cancer Res 2013;73:2104-2116.
88. Muranski P, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008;112:362-373.
89. Guerau-de-Arellano M, Martinic M, Benoist C, Mathis D. Neonatal tolerance revisited: a perinatal window for Aire control of autoimmunity. J Exp Med 2009;206:1245-1252.
90. Laakso SM, et al. Regulatory T cell defect in APECED patients is associated with loss of naive FOXP3(+) precursors and impaired activated population. J Autoimmun 2010;35:351-357.
91. Kekalainen E, et al. A defect of regulatory T cells in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Immunol 2007;178:1208-1215.
92. Aschenbrenner K, et al. Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells. Nat Immunol 2007;8:351-358.
93. Lei Y, et al. Aire-dependent production of XCL1 mediates medullary accumulation of thymic dendritic cells and contributes to regulatory T cell development. J Exp Med 2011;208:383-394.
94. Samy ET, Wheeler KM, Roper RJ, Teuscher C, Tung KS. Cutting edge: autoimmune disease in day 3 thymectomized mice is actively controlled by endogenous disease-specific regulatory T cells. J Immunol 2008;180:4366-4370.
95. Samy ET, Parker LA, Sharp CP, Tung KS. Continuous control of autoimmune disease by antigen-dependent polyclonal CD4+CD25+ regulatory T cells in the regional lymph node. J Exp Med 2005;202:771-781.
96. Huang AY, et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-965.
97. Spiotto MT, et al. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002;17:737-747.
98. Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med 2004;10:294-298.
99. Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev 2010;234:142-162.
100. Mathis D, Benoist C. Aire. Annu Rev Immunol 2009;27:287-312.
101. Hinterberger M, et al. Autonomous role of medullary thymic epithelial cells in central CD4(+) T cell tolerance. Nat Immunol 2010;11:512-519.
102. Koble C, Kyewski B. The thymic medulla: a unique microenvironment for intercellular self-antigen transfer. J Exp Med 2009;206:1505-1513.